Karyopharm Therapeutics Inc. Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Karyopharm Therapeutics Inc. (KPTI) reported Effective Income Tax Rate Reconciliation, Other Adjustments, Percent of 0.10% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments · last filed 2026-02-13
- Karyopharm Therapeutics Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2025 was 0.10%, a 96.67% decline from fiscal 2024.
- Karyopharm Therapeutics Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2024 was 3.00%.
- Karyopharm Therapeutics Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2023 was -0.80%, a 125.81% decline from fiscal 2022.
- Karyopharm Therapeutics Inc. effective income tax rate reconciliation, other adjustments, percent for fiscal 2022 was 3.10%, a 244.44% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent 12 month as first filed |
|---|---|---|
| 2025-12-31 | 0.10% 10-K · filed 2026-02-13 | |
| 2024-12-31 | 3.00% 10-K · filed 2026-02-13 | |
| 2023-12-31 | -0.80% 10-K · filed 2026-02-13 | |
| 2022-12-31 | 3.10% 10-K · filed 2025-02-19 | -3.10% 10-K · filed 2023-02-17 |
| 2021-12-31 | 0.90% 10-K · filed 2024-02-29 | |
| 2020-12-31 | -0.30% 10-K · filed 2023-02-17 | 1.20% 10-K · filed 2021-02-24 |
| 2019-12-31 | -0.10% 10-K · filed 2022-03-01 | -0.40% 10-K · filed 2020-02-26 |
| 2018-12-31 | -0.60% 10-K · filed 2021-02-24 | |
| 2017-12-31 | -1.40% 10-K · filed 2020-02-26 | |
| 2015-12-31 | 1.00% 10-K · filed 2018-03-15 | |
| 2014-12-31 | 2.80% 10-K · filed 2017-03-16 | |
| 2013-12-31 | -0.80% 10-K · filed 2016-03-15 | |
| 2012-12-31 | 0.00% 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |